Revolution Medicines (RVMD) closed at $162.69 on November 17, 2026, down 2.5% from the previous close, on volume of 1,991,657 shares (30-day average 2,272,815).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Put Spread | 20-Nov-26150 : 175 P | 6,002 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 17-Nov 6:30 AM ET)
Globe Newswire (Mon, 16-Nov 1:00 PM ET)
Revolution Medicines Earnings Call Signals Strong Launch Momentum
TipRanks (Sat, 14-Nov 8:49 PM ET)
Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)
TipRanks (Fri, 13-Nov 1:25 AM ET)
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Globe Newswire (Wed, 4-Nov 4:02 PM ET)
Revolution Medicines to Participate in November 2026 Investor Conferences
Globe Newswire (Tue, 27-Oct 4:05 PM ET)
Globe Newswire (Fri, 23-Oct 7:30 AM ET)
Globe Newswire (Wed, 21-Oct 4:05 PM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Revolution Medicines trades on the NASDAQ stock market under the symbol RVMD.
As of November 18, 2026, RVMD stock price declined to $159.79 with 1,002,624 million shares trading.
RVMD has a beta of 2.09, meaning it tends to be more sensitive to market movements. RVMD has a correlation of 0.14 to the broad based SPY ETF.
RVMD has a market cap of $34.25 billion. This is considered a Large Cap stock.
Last quarter Revolution Medicines reported $198 million in Revenue and -$1.90 earnings per share. This beat revenue expectation by $170 million and exceeded earnings estimates by $.47.
In the last 3 years, RVMD traded as high as $224.31 and as low as $20.51.
The top ETF exchange traded funds that RVMD belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
RVMD has outperformed the market in the last year with a return of +131.1%, while the SPY ETF gained +10.8%. However, in the most recent history, RVMD shares have underperformed the stock market with its stock returning -24.6% in the last 3 month period and -17.7% for the last 2 week period, while SPY has returned -5.3% and -3.2%, respectively.
RVMD support price is $157.18 and resistance is $168.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVMD shares will trade within this expected range on the day.